Dated changes · last-verified stamps · built November 11, 2026
Assistance program status board: what changed, and when we last checked
Manufacturer programs change their rules under readers' feet, and most pages that list them carry no date. This board records only what we have read on a program's own page, each with the date we read it and how we checked it. It is short today and grows with every comparison of a program's page against its last saved copy.
Changes and offers we have recorded
Looking for disease funds run by charities, such as Blood Cancer United and the Patient Advocate Foundation? See the charitable copay fund board.
- Medicaid Prescription Drug Coveragestatus: limited
HealthCare.gov states that from January 1, 2027, in states that provide Medicaid coverage to adults based on income alone, a person may need to meet a new monthly work requirement to qualify for or keep Medicaid coverage. It adds that a person who lost or was denied Medicaid for not meeting a state work requirement may get Marketplace coverage but will not qualify for savings on Marketplace plan costs.
Took effect January 1, 2027. Read November 7, 2026; quote matched against the saved page text. Source page.
- Novo Nordisk Patient Assistance Programstatus: limited
Novo Nordisk states that Medicare beneficiaries with prescription drug coverage will no longer be eligible to receive Ozempic through its Patient Assistance Program, and that some medicines will no longer be part of the program for 2026 (the page points to a separate list of the medicines that remain covered).
Read November 7, 2026; quote matched against the saved page text. Source page.
- Novo Nordisk Patient Assistance Program (Ozempic)status: limited
Novo Nordisk states that Medicare beneficiaries with prescription drug coverage will no longer be eligible to receive Ozempic through its Patient Assistance Program, and that some medicines will no longer be part of the program for 2026 (the page points to a separate list of the medicines that remain covered).
Read November 7, 2026; quote matched against the saved page text. Source page.
- HealthWell Foundationstatus: limited
The HealthWell Foundation homepage lists disease funds as Open or Closed when read. Closed funds include Type 2 Diabetes, Migraine and Multiple Sclerosis - Medicare Access; open funds include Multiple Myeloma - Medicare Access, which the page says offers up to $8,000 in prescription drug copayment or Medicare Part B premium assistance. The page carries no fund-level date; the status is as of the read.
Read November 7, 2026; quote matched against the saved page text. Source page.
- Ozempic Savings Card (Novo Nordisk)savings card
The NovoCare Ozempic savings-offer page states: pay as little as $25 per month for up to a 3-month prescription with commercial insurance, subject to a maximum savings of $100 per month; government beneficiaries are excluded.
Read November 7, 2026; quote matched against the saved page text. Source page.
- eliquis copay cardsavings card
The Eliquis savings-and-support page states a Co-pay Card: pay as little as $10 for a 30-day supply or for the first 90-day supply, as little as $30 for subsequent 90-day refills for up to 24 months, with a maximum annual benefit of $2,000. Activation and first use must take place by December 31, 2026, and the card expires 24 months from activation.
Limited time: Activation and first use must take place by December 31, 2026.
Read November 7, 2026; quote matched against the saved page text. Source page.
- wegovy medicare bridge priceoffer
The NovoCare Wegovy page states that starting July 1 Medicare patients pay $50 per month for Wegovy through the Medicare GLP-1 Bridge program, for adults prescribed Wegovy for weight loss only. The page does not state the year or an end date.
Read November 7, 2026; quote matched against the saved page text. Source page.
- wegovy pill novocare self payself-pay price
The NovoCare Wegovy page states self-pay prices for the Wegovy pill by dose: $149 per month for 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg, where one month is a bottle of 30 tablets. No end date is stated for the pill prices.
Read November 7, 2026; quote matched against the saved page text. Source page.
- trintellix savings cardsavings card
The Trintellix page states a Savings Card for commercially insured patients aged 18 and older: as little as $10 for a 30- or 90-day prescription, with savings of up to $100 per 30-day or $300 per 90-day prescription and maximum total savings of $1,300 over one year. The program will end on December 31, 2026.
Limited time: The Savings Card program will end on December 31, 2026.
Read November 7, 2026; quote matched against the saved page text. Source page.
- trintellix direct purchaseself-pay price
The Trintellix page states a price without using insurance of $299 for a 30-day prescription and a list price of $540.00 for a 30-day prescription as of 01/01/2026. The page states eligibility requirements apply; no end date is stated for this price.
Read November 7, 2026; quote matched against the saved page text. Source page.
- xarelto copay cardsavings card
The J&J withMe Xarelto page states pay as little as $10 per fill for patients with commercial or private insurance, with a maximum annual program benefit of $3,975 and limits to savings per fill. No end date is stated.
Read November 7, 2026; quote matched against the saved page text. Source page.
- humira complete savings cardsavings card
The Humira Complete page states a Savings Card for commercially insured patients with a cost as little as $0 per month, subject to a maximum annual benefit of $14,000 per calendar year. No end date is stated.
Read November 7, 2026; quote matched against the saved page text. Source page.
- linzess savings cardsavings card
The LINZESS savings page states pay as little as $30 per 30, 60 or 90-day supply for each of up to twelve prescription fills per calendar year, with a maximum annual benefit of $2,280.00 per calendar year, for commercially insured patients. No end date is stated.
Read November 7, 2026; quote matched against the saved page text. Source page.
- ocrevus copay programsavings card
The Ocrevus financial-support page states a Co-pay Program for commercially insured patients: as little as $0 per treatment, with co-pay assistance of up to $20,000 per calendar year, and administration assistance up to $1,500 per calendar year in the first year and up to $1,000 each calendar year after. Maximum benefits reset every January 1st.
Read November 7, 2026; quote matched against the saved page text. Source page.
- stelara savings programsavings card
The J&J withMe Stelara page states pay as little as $5 per dose for patients using commercial or private insurance. A maximum program benefit per calendar year applies but the amount is not stated in the text read; terms expire at the end of each calendar year and may change.
Read November 7, 2026; quote matched against the saved page text. Source page.
- gilead copay savings programsavings card
The Gilead Advancing Access page lists co-pay savings of up to $8,500 per calendar year (Bixlenvo), $8,000 (Yeztugo), $9,600 (Sunlenca), $7,200 (Biktarvy, Descovy, Genvoya, Truvada), $6,000 (Odefsey, Stribild, Complera), $3,600 with a $300 monthly maximum (Emtriva) and $600 with a $50 monthly maximum (Tybost). Yeztugo and Sunlenca amounts include up to $100 per visit for injection administration. The card auto-renews January 1 each year.
Read November 7, 2026; quote matched against the saved page text. Source page.
- cosentyx bridge program free supplyoffer
The Cosentyx support page states a Bridge Program (Covered Until You Are Covered) that can provide up to 2 years of Cosentyx Subcutaneous Injection for free while coverage is sought, or until insurance approval if earlier, with conditions stated on the page.
Read November 7, 2026; quote matched against the saved page text. Source page.
- ozempic novocare self payself-pay price
The NovoCare Ozempic savings-offer page states a self-pay price: $199 per month for the first 2 monthly fills of the 0.25 mg and 0.5 mg pen through December 31, 2026, then $349 per month for 0.25, 0.5 or 1 mg and $499 per month for 2 mg; its pricing table also shows self pay starting at $149 per month for a 1.5 mg dose. Marked a limited time offer; pricing to be updated after December 31, 2026.
Limited time: Pricing to be updated after December 31, 2026.
Read November 7, 2026; quote matched against the saved page text. Source page.
- wegovy novocare self payself-pay price
The NovoCare Wegovy savings-offer page states a self-pay price: $199 per month for the first 2 monthly fills of the 0.25 mg and 0.5 mg dose through December 31, 2026, then $349 per month for 0.25 to 2.4 mg and $399 per month for Wegovy HD 7.2 mg; its pricing table shows self pay starting at $149 per month. Marked a limited time offer; pricing to be updated after December 31, 2026.
Limited time: Pricing to be updated after December 31, 2026.
Read November 7, 2026; quote matched against the saved page text. Source page.
- eliquis free trial offeroffer
The Eliquis savings-and-support page states a Free 30-Day Trial offer: a free 30-day supply (up to 74 tablets) of ELIQUIS for eligible first-time patients with a valid 30-day prescription, one use per patient per lifetime, not billable to insurance or government programs, with the card expiring on December 31, 2026.
Limited time: The card expires on December 31, 2026.
Read November 7, 2026; quote matched against the saved page text. Source page.
- eliquis direct purchaseself-pay price
The Eliquis savings-and-support page states that a patient without insurance may be eligible to purchase ELIQUIS directly through ELIQUIS 360 Support. The page gives no price; it links to pricing information that was not read.
Read November 7, 2026; quote matched against the saved page text. Source page.
- ozempic novocare self payself-pay price
The NovoCare Ozempic savings-offer page states: self pay starting at $149 per month (1.5 mg dose) and $199 per month for the first 2 months for new patients, a limited time offer with pricing to be updated after December 31, 2026. The page shows separate pill and pen selections; which price belongs to which could not be determined from the saved page text.
Limited time: Pricing to be updated after December 31, 2026.
Read November 7, 2026; quote matched against the saved page text. Source page.
- Boehringer Ingelheim Cares Foundationstatus: limited
No new patient enrollments for individuals with Medicare Part D or Medicare Advantage prescription drug coverage for Boehringer Ingelheim primary care products (Combivent Respimat, Glyxambi, Jardiance, Jentadueto, Jentadueto XR, Spiriva Respimat, Stiolto Respimat, Synjardy, Synjardy XR, Tradjenta, Trijardy XR). Part D patients actively enrolled as of 2026-10-15 continue through their current enrollment period and may be eligible in 2027 only after annual re-enrollment. Product removals: Cyltezo 2026-07-15; OFEV 2026-09-11 (active patients continue through the end of their enrollment or 2027-12-31); no new enrollments for Aptivus, Atrovent and Striverdi from 2026-10-15.
Took effect October 15, 2026. Read November 6, 2026; read by a person on the program’s own document. Source page.
- Novartis Patient Assistance Foundationstatus: limited
The Novartis Patient Assistance Foundation page states that for patients who applied for NPAF support on or after July 27, 2026, a new Patient Enrollment Portal is used: approved patients are encouraged to use it to re-fill medication, and patients told their application is missing information are encouraged to upload documents through it. The page lists no end date.
Took effect July 27, 2026. Read November 7, 2026; quote matched against the saved page text. Source page.
- AstraZeneca AZ&Me Prescription Savingsstatus: limited
AZ&Me no longer accepts new patients for FARXIGA and XIGDUO XR from 2026-05-01; actively enrolled patients continue until 2026-12-31; the notice says generic equivalents became available beginning in April 2026 and that the products will be removed from the program by the end of 2026; communications went to enrolled patients and providers in April 2026
Took effect May 1, 2026. Read November 6, 2026; read by a person on the program’s own document. Source page.
- Pfizer RxPathwaysstatus: limited
Pfizer RxPathways states that from 2025-01-01 Medicare Part D patients must first enroll in the Medicare Prescription Payment Plan and submit proof of enrollment with their application, and, before being considered, must apply to all open, relevant diagnosis-specific independent charitable patient assistance programs and submit written proof of any denial. The page that states this is headed 2025 PAP changes; no later update was on the page when read.
Took effect January 1, 2025. Read November 7, 2026; quote matched against the saved page text. Source page.
Last verified: ceilings checked against the program's own document
For each program below we compared the income ceiling we publish with the program's own page or document. The finder at /tools/assistance-finder shows these ceilings against your income.
| Program | Ceiling we publish | How it was checked | Date read |
|---|---|---|---|
| Pfizer RxPathways | Income at or below 300% FPL ($47,880 for one person in 2026) | quote matched against the saved page text | November 6, 2026 |
| Merck Helps (Merck Patient Assistance Program) | Income at or below $79,800 for one person for KEYTRUDA, or $63,840 for JANUVIA and JANUMET | unverifiable | November 6, 2026 |
| Sanofi Patient Connection | Income at or below 400% FPL ($63,840 for one person) | quote matched against the saved page text | November 6, 2026 |
| Novartis Patient Assistance Foundation | Income at or below $63,840 for one person, $86,560 for two (NPAF eligibility tool, read 13 October 2026) | unverifiable | November 6, 2026 |
| GSK Patient Assistance Program | Income at or below $47,880 for one person (300% FPL) | unverifiable | November 6, 2026 |
| Genentech/Roche Access Solutions | Household income under $150,000 for 1 to 4 people if uninsured or your plan does not cover the medicine (Genentech Patient Foundation) | unverifiable | November 6, 2026 |
| Keytruda Patient Assistance (Merck) | Income at or below $79,800 for one person, $108,200 for a couple (500% FPL) | unverifiable | November 6, 2026 |
| Medicare Extra Help (Low Income Subsidy) | Income up to $23,940 a year for one person in 2026 (150% FPL), with resource limits | unverifiable | November 6, 2026 |
| Medicaid Prescription Drug Coverage | Generally up to 138% FPL in expansion states; lower in non-expansion states | quote matched against the saved page text | November 6, 2026 |
| HealthWell Foundation | Up to 300% to 500% FPL depending on the disease fund; many funds close to new patients | quote matched against the saved page text | November 6, 2026 |
| Lilly Cares Foundation | Income at or below 300%, 400% or 500% FPL depending on the Lilly Cares group of your medicine ($47,880, $63,840 or $79,800 for one person) | read by a person on the program’s own document | November 6, 2026 |
| AstraZeneca AZ&Me Prescription Savings | Income at or below 300% FPL for primary and specialty medicines (500% for the rare disease medicine Wainua) | read by a person on the program’s own document | November 6, 2026 |
| Boehringer Ingelheim Cares Foundation | Income at or below 250% FPL ($39,900 for one person), or 200% ($31,920) for the Respimat inhalers. Since 15 October 2026 no new Medicare Part D or Advantage enrollments for its primary care products, including Jardiance | read by a person on the program’s own document | November 6, 2026 |
| myAbbVie Assist | Income at or below $63,840 for one person, $86,560 for two, $109,280 for three or $132,000 for four, plus $22,720 for each extra person (myAbbVie Assist income criteria, 400% of the 2026 guideline) | unverifiable | October 29, 2026 |
| Johnson & Johnson Patient Assistance Program | Income at or below $46,950 for one person or $63,450 for two (J&J 2026 program limit, 300% of the 2025 poverty guideline) | unverifiable | October 19, 2026 |
| Amgen Safety Net Foundation | Income at or below $47,880 for one person (300% FPL), and no insurance coverage | unverifiable | October 19, 2026 |
| Regeneron/Sanofi Dupixent MyWay | No published income limit: DUPIXENT MyWay reviews eligibility case by case | unverifiable | October 19, 2026 |
| Bristol Myers Squibb Patient Assistance Foundation | Income at or below $47,880 for one person for Eliquis (BMS Patient Assistance Foundation, read 13 October 2026) | unverifiable | October 13, 2026 |
Questions
Does this list every program that changed?
No. It lists only changes we have recorded from a program’s own page, each with its date. A program missing here may have changed without our having read it. The board grows as we record more.
What does "last verified" mean?
The date we read the program’s own page or document and checked the income ceiling we publish against it, with how it was checked: read by a person, or a quote matched mechanically against the saved page text.
How do you find changes?
We keep dated, hashed copies of each program’s source pages and compare each new copy with the last. A person then reads any page that changed before a fact is recorded.
Sources and terms. Each entry links its source page. Facts only; no program text is copied beyond short statements, and each is attributed. Every fact is stored with its source, date and proof state: see where every figure comes from. Eligibility is decided by each program, not by us. Not medical, legal or financial advice. Licence the data.